TAU Ventures — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
AmplifyMD offers a virtual care platform with EHR integrations, automation, embedded AI tools, and a network of remote specialists that lets hospitals and health systems expand physician capacity and add specialty services.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSLos Gatos, US
Anand Nathan(Co-Founder & Chief Product Officer)inMeena Mallipeddi(Co-Founder & Chief Executive Officer)inMohan Mallipeddi, MD(Chief Medical Officer)inNijay Patel(Chief Technology Officer)inKurt Blasena(Chief Commercial Officer)in
BoardStephen K. Klasko(Board of Directors)
Co-investorsF-Prime CapitalForerunner VenturesGreylock PartnersTau Ventures
Cascala develops clinical intelligence tools that combine medicine, engineering, product design, and AI to deliver relevant data at the point of care.
AI & Machine LearningDigital HealthHealthtech
Matt A. Murphy(Founder)in
Co-investorsFlare Capital PartnersRedesign HealthTau VenturesEniac Ventures
Olli Health develops clinical AI technology for home health agencies.
AI & Machine LearningDigital HealthHealthtechNew York City, US
Eric Steege(Co-founder & CEO)Joe Freudenthal(Co-founder & COO)Jeremy Gordon(Co-founder & CTO)
Co-investorsEquitage Ventures, L.L.C.Tau VenturesTechstarsArkitekt VenturesCannage CapitalIndustry Ventures
Qore provides multi-tenant core banking infrastructure and related technology, including automated lending, cloud-based API integrations, account management, card services, analytics, and white-label solutions.
Cloud ComputingFintechSaaS
Co-investorsLateral CapitalGreen Visor CapitalSilverton Partners
Spektion is a vulnerability management platform that analyzes software in an organization's environment to determine what is actually exploitable, factoring in whether software is running, its privileges, network exposure, and blast radius.
CybersecurityEnterprise SoftwareSaaS
Co-investorsDauntless VenturesTau VenturesLiveOak Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.